Johnson & Johnson exceeded revenue and profit expectations in Q1, driven by strong sales of cancer treatments like Darzalex. The company reported $21.89 billion in sales, with adjusted earnings of $2.77 per share.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing